SHORT REPORT

Increased interictal cerebral glucose metabolism in a cortical-subcortical network in drug naive patients with cryptogenic temporal lobe epilepsy

Massimo Franceschi, Giovanni Lucignani, Angelo Del Sole, Chiara Grana, Sergio Bressi, Fabio Minicucci, Cristina Messa, Maria Paola Canevini, Ferruccio Fazio

Abstract
Positron emission tomography with \[^{18}F\]-2-fluoro-2-deoxy-D-glucose (\[^{18}F\]FDG) has been used to assess the pattern of cerebral metabolism in different types of epilepsies. However, PET with \[^{18}F\]FDG has never been used to evaluate drug naive patients with cryptogenic temporal lobe epilepsy, in whom the mechanism of origin and diffusion of the epileptic discharge may differ from that underlying other epilepsies. In a group of patients with cryptogenic temporal lobe epilepsy, never treated with antiepileptic drugs, evidence has been found of significant interictal glucose hypermetabolism in a bilateral neural network including the temporal lobes, thalami, basal ganglia, and cingular cortices. The metabolism in these areas and frontal lateral cortex enables the correct classification of all patients with temporal lobe epilepsy and controls by discriminant function analysis. Other cortical areas—namely, frontal basal and lateral, temporal mesial, and cerebellar cortices—had bilateral increases of glucose metabolism ranging from 10 to 15% of normal controls, although lacking stringent statistical significance. This metabolic pattern could represent a pathophysiological state of hyperactivity predisposing to epileptic discharge generation or diffusion, or else a network of inhibitory circuits activated to prevent the diffusion of the epileptic discharge.

Keywords: epilepsy; cryptogenic temporal lobe epilepsy; refractory epilepsy; PET/\[^{18}F\]FDG

Cryptogenic partial epilepsies are disorders with an unknown and occult aetiology. Although MRI has greatly improved our ability to uncover anatomical lesions in these patients, our ignorance of a presumed cause may be due to low sensitivity of our diagnostic tools.

The assessment of cerebral metabolism by PET with \[^{18}F\]-2-fluoro-2-deoxy-D-glucose (\[^{18}F\]FDG) has improved our knowledge on the metabolism in the epileptogenic zone and on the pattern of diffusion of the epileptic discharge in different types of epilepsies. Indeed, PET/\[^{18}F\]FDG now has a well established clinical role in the presurgical evaluation of patients with drug resistant temporal lobe epilepsy. Temporal lobe epilepsy is often symptomatic of cerebral lesions which are commonly found by MRI, but are sometimes detectable only by PET/\[^{18}F\]FDG.

Different mechanisms of origin and diffusion of the epileptic discharge may underlie symptomatic and cryptogenic temporal lobe epilepsies. The assessment of cerebral metabolism in patients with cryptogenic temporal lobe epilepsy could help to understand the pathophysiological mechanisms of this type of seizure and eventually to reclassify individual patients.

The purpose of this study was the assessment of interictal regional cerebral glucose utilisation (rCMRglu) in patients not taking drugs and in whom the clinical diagnosis of cryptogenic epilepsy was made for the first time just before the study. Thus we investigated the early phases of cryptogenic temporal lobe epilepsy and avoided the possibility of artifactual findings due to the effects of antiepileptic treatment.

Subjects and methods
PATIENTS
We studied 13 consecutive patients (10 women and three men, mean age 31-8, range 17-53 years) in whom the diagnosis of cryptogenic temporal lobe epilepsy was made according to standard criteria (table 1).

None of the patients with temporal lobe epilepsy had ever had a diagnosis of epilepsy before the enrolment in the study, not even those with a long history of disease, probably because of the little impact on their daily life of rare and benign partial seizures. For this reason they had never been treated with antiepileptic drugs.

Their first seizure occurred between six months and 27 years before the diagnosis (mean 4 (SD 7) years) and they reported a variable number of seizures (mean 8 (SD 12); range 3-50) during the entire course of the disease.

Eleven patients had only complex partial
seizures and two patients had both simple and complex partial seizures. Six patients reported one to three episodes of secondary generalisation, usually during sleep. Interictal waking or sleep EEG recordings showed epileptic abnormalities localised in the left (six patients), in the right (five patients), or in both (two patients) temporal regions. An ictal EEG could not be recorded in any of the patients examined.

None of the patients had relevant neurological or systemic disease, and brain MRI was normal; MRI was performed with a 1.5 Tesla superconducting unit, using contiguous axial and coronal slices of 5 mm thickness and multiple spin echo sequences (TR = 2400 ms; T1 = 500/17 ms; T2 = 15/50 ms). Because the accuracy of MRI evaluation is critical in the diagnosis of cryptogenic temporal lobe epilepsy, an expert unblinded neuroradiologist was asked to rule out possible structural abnormalities in the mesial temporal lobe.

Patients underwent the PET/[^18F]FDG study at least three days after their last seizure. Scalp EEG monitoring, initiated at least 30 minutes before giving[^18F]FDG, and carried out up to the end of the PET examination, did not show subclinical seizures or epileptic patterns other than those in the patients' previous EEG recordings.

**CONTROLS**

Control subjects were 13 normal healthy age-matched volunteers, mean age 34.2, range 18–59 years, and with no history of drugs or seizures.

Permission for the study was given by the ethics committee of the Scientific Institute H San Raffaele.

**PET METHODS**

The[^18F]FDG was synthesised as previously described with a compact automated module connected to the cyclotron (Siemens-CTI RDS 112 cyclotron, Siemens/CPS, Knoxville, TN, USA) and used within one hour of its preparation. Quality control procedures for the tracers were carried out routinely according to methods previously described and[^18F]FDG with radiochemical purity higher than 95% was used. We used an ECAT 931/04–12 tomograph (CPS/Siemens, Knoxville, TN, USA) with a transverse field of view of 55.5 cm and an axial field of view of 5.4 cm. All subjects were studied in the resting state with their eyes open and ears unplugged. Before each study a 20 gauge teflon catheter was inserted into the radial artery, under local anaesthesia; the patients were then positioned in the PET scanner and their heads were restrained by a customised head holder. The orbitomeatal line was symmetrically defined with the aid of low energy laser beams and skin marks and the PET gantry was aligned to obtain axial slices parallel to the orbitomeatal line. Two 10 minute consecutive transmission scans, one for each bed position necessary to examine the whole brain, were performed with a "Ge" source external to the subject to measure the coefficients to correct for attenuation of the emitted photons. At the end of the transmission scan each subject received an intravenous injection of about 250 MBq of[^18F]FDG. Timed arterial blood samples were collected continuously for the first minute after the tracer injection and then at increasing intervals throughout the PET study, to assay the plasma concentration of glucose and "F. Emission scans were carried out between 45 and 70 minutes after intravenous[^18F]FDG injection. Data were acquired from two sets of seven equally spaced transaxial planes (four direct and three cross planes; slice thickness 6–75 mm) parallel to the orbitomeatal line and covering an axial field of view of 10–8 cm. Scans were reconstructed with a Hann Filter with a cut off frequency of 0.5 cycles per pixel. Under these conditions, the spatial resolution in the image plane was 8 mm full width at half maximum. Each image was reconstructed on a 128 × 128 matrix with a pixel size of 1.56 mm. Correction for attenuation of the 512 KeV γ rays by the tissue was performed with the coefficients obtained from the transmission scan. Average values of regional cerebral metabolic rate for glucose (rCMRglu) were calculated in each region of interest based on the plasma glucose and "F assays according to a model with the three rate constants operational equation of Sokoloff et al using the kinetic constants and lumped constant reported by Reivich et al.13

**PET DATA ANALYSIS**

Reconstructed images were transferred to a SUN SPARC workstation for the analysis. Circular regions of interest, with a diameter of 9–6 mm (1.5 full width at half maximum), were drawn on 14 anatomofunctional cortical, subcortical, and cerebellar structures, identified from the atlas of Damasio and Damasio. Mean rCMRglu values for each of the 14 structures were calculated by averaging the rCMRglu values of the multiple regions of interest included in each anatomical region. These average values were used for the data analysis.

**STATISTICAL ANALYSIS**

All analyses were with the SPSS package.15 A repeated measures analysis of variance
Values are means (SD) (95% CI); TLE = temporal lobe epilepsy.

<table>
<thead>
<tr>
<th>Group</th>
<th>Value</th>
<th>Controls</th>
<th>ANCOVA value</th>
<th>ANCOVA adjusted value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left hemisphere</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TLE patients</td>
<td>6.44 (0.62) (6.06-8.82)</td>
<td>6.35 (0.72) (5.91-7.68)</td>
<td>0.25</td>
<td>2.51</td>
</tr>
<tr>
<td>Controls</td>
<td>6.46 (0.62) (5.68-8.83)</td>
<td>6.45 (0.61) (5.90-7.01)</td>
<td>0.82</td>
<td>2.58</td>
</tr>
<tr>
<td>Right hemisphere</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TLE patients</td>
<td>7.69 (1.13) (7.00-8.38)</td>
<td>7.68 (0.89) (6.60-7.68)</td>
<td>1.80</td>
<td>1.98</td>
</tr>
<tr>
<td>Controls</td>
<td>7.51 (0.96) (6.92-8.09)</td>
<td>6.60 (0.50) (6.23-6.93)</td>
<td>10.18*</td>
<td>9.88*</td>
</tr>
</tbody>
</table>

**Discussion**

In a group of patients with cryptogenic temporal lobe epilepsy who were never treated with antiepileptic drugs, we have found evidence of significant interictal hypermetabo-
lism in a bilateral neural network including the temporal lobes, thalami, basal ganglia, and cingular cortices. Applying the metabolism of these areas and of lateral frontal regions in the model of discriminant function analysis, all patients with temporal lobe epilepsy and normal controls could be correctly assigned to each category. Although lacking stringent statistical significance, several other cortical areas had bilateral increases of rCMRGlu ranging from 10% to 15%. These areas were the frontal basal, frontal lateral, temporal mesial, and cingular cortices, all of which are known to be functionally correlated to the significantly hypermetabolic network. By contrast, the Rolandic, parietal, and occipital areas showed minimal increases, ranging from 0.5% to 7% in comparison with normal subjects.

This finding is surprising because previous interictal studies of patients with refractory temporal lobe epilepsy have shown in most cases unilateral areas of temporal hypometabolism, usually concordant with the side of the EEG abnormalities and with the site of a morphological lesion. Interictal hypermetabolism has been occasionally reported: in episodic cases of children with refractory temporal lobe epilepsy, bilaterally in lenticular nuclei of children with infantile spasms, and in the thalamus contralateral to mesial gliosis in patients with refractory temporal lobe epilepsy. On the contrary, a widespread hypermetabolism is usually found during seizures or in the postictal period in patients with refractory temporal lobe epilepsy.

Hypermetabolism due to seizures can be reasonably excluded in our patients as they had been seizure free for at least three days before the PET/18F FDG study. Moreover, EEG monitoring excluded seizures 30 minutes before and during the PET/18F FDG study. The unlikely possibility of a localised subclinical discharge in the mesial structures undetected by scalp EEG cannot be ruled out.

The apparent discrepancies between these and previous findings can have several explanations. The population of epileptic patients examined in this study was different from those previously examined. In particular, our patients: (a) had a diagnosis of cryptogenic and not of symptomatic temporal lobe epilepsy; (b) had a mild illness; (c) were not taking medication. Patients with cryptogenic epilepsies are less commonly drug resistant and less severely ill than patients with symptomatic epilepsies. Abnormal MRI findings, including mesial gliosis or neoplasms, are often found in patients with refractory temporal lobe epilepsy. These patients, often with long lasting, frequent, and severe seizures, may have had a spontaneous kindling phenomenon, or even sequelae of cerebral trauma, further complicating cerebral metabolic patterns. Patients with cryptogenic temporal lobe epilepsy and normal MRI may have a pattern of origin and discharge of epileptogenic discharges different from that of patients with temporal lobe epilepsy refractory to antiepileptic drugs. All patients with refractory temporal lobe epilepsy studied with PET/18F FDG and reported in the medical literature were having long term antiepileptic treatment, often with more than one drug. This was likely to induce a decrease in cerebral glucose metabolism.

Our finding of a bilateral hypermetabolic network contrasts with the hypothesis of well localised epileptogenic zones underlying the pathophysiology of cryptogenic temporal lobe epilepsy. This pattern is, however, in agreement with the clinical finding that often in cryptogenic temporal lobe epilepsy neither seizure phenomenology nor EEG are clearly lateralising or localising the epileptogenic zone. For example, in our sample no patient had lateralising signs in their seizures (which were mainly amygdalohippocampal and secondarily generalised), two patients out of 13 had bilateral EEG abnormalities, and six patients showed lateralising EEGs only during sleep recordings.

The bilateral hypermetabolic network found in a group of untreated patients with cryptogenic temporal lobe epilepsy could represent a pathophysiological state of hyperactivity predisposing to epileptic discharge generation or diffusion, or a network of inhibitory circuits activated to prevent the diffusion of the epileptic discharge originating from a localised epileptogenic zone. In refractory cryptogenic temporal lobe epilepsy, focal neuronal loss and gliosis or alterations of synaptic processes seem to be the common causes of interictal glucose hypometabolism, whereas the ictal hypermetabolism could be related to energy consuming epileptic activity. Postictal hypermetabolism seems to be due to energy expenditure of inhibitory circuits for the restoration of normal membrane polarisation and chemical homeostasis. A similar mechanism could explain our finding of hypermetabolic bilateral networks in patients with cryptogenic temporal lobe epilepsy that cannot be ruled out.

The low frequency of their seizures, the mildness of the disease, and the long time (at least 72 hours) between the last seizure and the PET/18F FDG study. The hypothesis that the hyperactive network is the underlying pathophysiological basis of the disease seems to be more reasonable and could be confirmed by an ongoing follow up study in the same group of patients during chronic effective treatment with carbamazepine. Indeed, it cannot be ruled out that hypermetabolic networks may actually underlie most epileptic processes and could also be found in patients with refractory temporal lobe epilepsy if it were possible to study them when they were not taking drugs.

Whichever is the neurophysiological interpretation, the finding of a hypermetabolic network in cryptogenic temporal lobe epilepsy suggests the existence of different mechanisms of origin and diffusion of the epileptogenic discharge and a different functional balance between "normal" and "lesioned" cerebral areas in different types of epilepsies. This in turn points out the need for metabolic...
Hypermetabolic neural network in temporal lobe epilepsy

Increased interictal cerebral glucose metabolism in a cortical-subcortical network in drug naive patients with cryptogenic temporal lobe epilepsy.

M Franceschi, G Lucignani, A Del Sole, C Grana, S Bressi, F Minicucci, C Messa, M P Canevini and F Fazio

*J Neurol Neurosurg Psychiatry* 1995 59: 427-431
doi: 10.1136/jnnp.59.4.427

Updated information and services can be found at:
[http://jnnp.bmj.com/content/59/4/427](http://jnnp.bmj.com/content/59/4/427)

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)